A phase one trial in France testing a new drug in humans has shattered the lives of at least a half dozen study participants. One person died this weekend, five more are hospitalized and three may have suffered permanent brain damage. Testing has been stopped, but the questions are just starting, We'll look at how drug trials are conducted in medical research hubs like Cleveland. We'll talk about the fallout from the tragedy in France and how that could impact the important work of drug development.
Resources:
Be Well: Cancer Research and Treatment
National Institutes of Health: clinicaltrials.gov
Dr. Davendra Sohal, MD, Oncologist, Cleveland Clinic Taussig Cancer Institute; Dr. Michael Reed, PharmD, Clinical Pharmacologist, University Hospitals; Dr. Nora McNamara, MD, Child and Adolescent Psychiatry, University Hospitals; Jacqui Lingler, Research Manager, University Hospitals; Kay Colby, Ideastream Health Unit